

( (S (NP-SBJ Food and Drug Administration
	     spokesman
             Jeff Nesbit)
     (VP said
         (SBAR 0
               (S (NP-SBJ the agency)
                  (VP has
                      (VP turned
                          (PRT over)
                          (NP evidence)
			  (PP-LOC in
				  (NP (NP a criminal investigation)
				      (VP concerning
					  (NP Vitarine Pharmaceuticals Inc.))))
                          (PP-CLR to
				  (NP (NP (NP the U.S. Attorney 's)
					  office)
				      (PP-LOC in
					      (NP Baltimore)))))))))
     .))
( (S (NP-SBJ-1 Neither
               (NP Vitarine)
               nor
               (NP (NP any)
                   (PP of
                       (NP (NP the
                               (NAC-LOC Springfield Gardens
					,
					N.Y.
					,)
                               company 's)
                           officials or employees))))
     (VP have
         (VP been
             (VP charged
                 (NP *-1)
                 (PP-CLR with
			 (NP any crimes)))))
     .))
( (S (NP-SBJ Vitarine)
     (VP (VP won
             (NP approval
		 (S (NP-SBJ *)
		    (VP to
			(VP market
			    (NP (NP a version)
				(PP of
				    (NP a blood pressure medicine))))))))
         but
         (VP acknowledged
             (SBAR that
                   (S (NP-SBJ it)
                      (VP substituted
                          (NP (NP a
				  SmithKline Beecham PLC
				  product))
			  (PP-CLR as
				  (NP its own))
                          (PP-LOC in
				  (NP tests)))))))
     .))
( (S (NP-SBJ Mr. Nesbit)
     (ADVP also)
     (VP said
         (SBAR 0
               (S (NP-SBJ the FDA)
                  (VP has
                      (VP asked
                          (NP-1 Bolar Pharmaceutical Co.)
                          (S (NP-SBJ *-1)
                             (VP to
                                 (VP recall
                                     (PP-LOC at
					     (NP the retail level))
                                     (NP its urinary tract antibiotic)))))))))
     .))
( (S (S-TPC-1 But
	      (ADVP-TMP so far)
	      (NP-SBJ the company)
	      (VP has n't
		  (VP complied
		      (PP-CLR with
			      (NP that request)))))
     ,
     (NP-SBJ the spokesman)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (S-TPC-2 (NP-SBJ-1 (NP Bolar)
			,
			(NP (NP the subject)
			    (PP of
				(NP (NP a criminal investigation)
				    (PP by
					(NP (NP the FDA)
					    and
					    (NP (NP (NP the Inspector General 's)
						    office)
						(PP of
						    (NP the 
							Health and Human Services Department))))))))
			,)
	      (VP (ADVP only)
		  agreed
		  (S (NP-SBJ *-1)
		     (VP to
			 (VP recall
			     (NP (NP two strengths)
				 (PP of
				     (NP (NP its version)
					 (PP of
					     (NP Macrodantin)))))
			     ``
			     (ADVP (ADVP as far down)
				   (PP as
				       (NP (NP direct customers)
					   ,
					   mostly
					   (NP wholesalers)))))))))
     ,
     ''
     (NP-SBJ Mr. Nesbit)
     (VP said
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S (NP-SBJ (NP Bolar)
	     ,
             (PP of
                 (NP (NP Copiague)
                     ,
                     (NP N.Y.)
                     ,)))
     (ADVP-TMP earlier)
     (VP began
         (NP (NP a voluntary recall)
             (PP of
                 (NP (NP both its 
			 (ADJP (ADJP 100 milligram) 
			       and 
			       (ADJP 50 milligram))
			 versions)
                     (PP of
                         (NP the drug))))))
     .))
( (S (NP-SBJ The FDA)
     (VP has
         (VP said
             (SBAR 0
                   (S (NP-SBJ it)
                      (VP presented
                          (NP (NP evidence)
			      (SBAR (WHNP-1 0)
				    (S (NP-SBJ it)
				       (VP uncovered
					   (NP *T*-1))))
			      (VP *ICH*-2))
			  (PP to
			      (NP the company))
			  (VP-2 indicating
				(SBAR that
				      (S (NP-SBJ-3 Bolar)
					 (VP substituted
					     (NP the brand-name product)
					     (PP-CLR for
						     (NP its own))
					     (S-PRP (NP-SBJ *-3)
						    (VP to
							(VP gain
							    (NP government approval
								(S (NP-SBJ *)
								   (VP to
								       (VP sell
									   (NP (NP generic versions)
									       (PP of
										   (NP Macrodantin)))))))))))))))))))
     .))
( (S (NP-SBJ Bolar)
     (VP has
         (VP denied
             (SBAR that
                   (S (NP-SBJ it)
                      (VP switched
                          (NP the brand-name product)
                          (PP-CLR for
				  (NP its own))
                          (PP-LOC in
				  (NP such testing)))))))
     .))
